

Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-5 (canceled)

Claim 6. (New): A method of rendering skin or mucosa permeable to 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone (Q10) comprising administration to the skin or mucosa of a patient a therapeutic formulation containing Q10 and an effective amount of protein-containing pulmonary surfactant in combination with excipients.

Claim 7. (New): The method of claim 6, characterized in that the therapeutic formulation further comprises liposomes.

Claim 8. (New): The method of claim 6, characterized in that the protein-containing pulmonary surfactant employed is a raw extract from an animal species.

Claim 9. (New): The method of claim 6, characterized in that administration is to oral mucosa.

Claim 10. (New): The method of claim 6, characterized in that administration is to pulmonary mucosa.

Claim 11. (New): The method of claim 6, characterized in that administration is to gastrointestinal mucosa.

Claim 12. (New): The method of claim 6, characterized in that administration is to vaginal mucosa.

Claim 13. (New): The method of claim 6, characterized in that administration is to the skin.

Claim 14. (New): A method of rendering skin or mucosa permeable to 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone (Q10) comprising administration to the skin or mucosa of a patient a therapeutic formulation containing Q10 and an effective amount of a complex of phospholipids, neutrolipids, and surfactant proteins.

Claim 15. (New): The method of claim 14, characterized in that the therapeutic formulation further comprises liposomes.

Claim 16. (New): The method of claim 14, characterized in that the protein-containing pulmonary surfactant employed is a raw extract from an animal species.

Claim 17. (New): The method of claim 14, characterized in that administration is to oral mucosa.

Claim 18. (New): The method of claim 14, characterized in that administration is to pulmonary mucosa.

Claim 19. (New): The method of claim 14, characterized in that administration is to gastrointestinal mucosa.

Claim 20. (New): The method of claim 14, characterized in that administration is to vaginal mucosa.

Claim 21. (New): The method of claim 14, characterized in that administration is to the skin.